News - April 6, 2020
Study: Economic & Financial Challenges of Developing Orphan Drugs
In a study commissioned by EUCOPE, the Office of Health Economics (OHE) assessed the extent to which the Orphan Medicinal Products (OMPs) Regulation (2000/018) has successfully incentivised companies to invest in research and development of OMPs.
The study also puts forward an analysis of the financial challenges of developing OMPs, and what the implications of changing the Regulation would be for companies’ future investment decisions.
For more information about EUCOPE’s work on OMPs, please contact Vittoria Carraro.